# Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

> **NCT00003335** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 44 (actual)

## Conditions studied

- Graft Versus Host Disease
- Leukemia
- Lymphoma
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **DRUG:** busulfan
- **DRUG:** cyclosporine
- **DRUG:** melphalan
- **DRUG:** methylprednisolone
- **PROCEDURE:** umbilical cord blood transplantation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00003335
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-01
- **Primary completion:** 2007-11
- **Final completion:** 2012-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2012-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003335, "Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00003335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*